EVOTEC SE INH O.N. (EVT)

Inhaber-Aktien o.N.

Sell: €6.822|Buy: €6.82|Change: 0.13 (1.91%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

€6.70

Previous close

€6.694

Trade high

€6.90

Volume

571,175

Year high

€10.62

Year low

€5.06

Dividend yield

–

Market capitalisation

€1.21 bn

P/E ratio

454.55

ISIN

DE0005664809

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Performance 21/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
EVOTEC SE INH O.N.	+ 1.91
More...

Company profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000employees and 18 production sites mainly in Europe and the United States.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.